MedTrace Logo

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

NCT01270724 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-10-27

Study results available
· View outcomes & findings →

Summary

This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.

Conditions

  • CNS Germ Cell Tumor

Interventions

DRUG

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).

Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.

Sponsors & Collaborators

  • Nationwide Children's Hospital

    lead OTHER

Principal Investigators

  • Randal Olshefski, MD · Nationwide Children's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2019-10-23
Completion
2019-12-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01270724 on ClinicalTrials.gov